Skip to main content
Press release November 5, 2026

Doximity Announces Fiscal 2027 Second Quarter Financial Results

Doximity, Inc. (DOCS)

Total revenues of $174.5 million, up 4% year-over-year Net income of $34.7 million, margin of 20% Adjusted EBITDA of $88.9 million, margin of 51% SAN FRANCISCO--(BUSINESS WIRE)-- Doximity, Inc. (NYSE: DOCS), the leading digital platform for U.S. medical professionals, today announced results of its fiscal 2027 second quarter ended September 30, 2026. “We delivered another quarter of record engagement while investing heavily in AI and maintaining a 51% adjusted EBITDA margin,” said Jeff Tangney, co-founder and CEO of Doximity. “More than 190 health systems have now purchased our AI suite, and with UpToDate and DoseCheck, we’re extending our lead in distribution and trust.” Fiscal 2027 Second Quarter Financial Highlights All comparisons, unless otherwise noted, are to the three months ended September 30, 2025. Revenue: Revenue of $174.5 million, versus $168.5 million, an increase of 4% year-over-year. Net income and non-GAAP net income: Net income of $34.7 million, versus $62.1 million, representing a margin of 19.9%, versus 36.8%. Non-GAAP net income of $68.3 million, versus $90.0 million, representing a margin of 39.1%, versus 53.4%. Adjusted EBITDA: Adjusted EBITDA of $88.9 million, versus $100.8 million, a decrease of 12% year-over-year, representing adjusted EBITDA margins of 50.9%, versus 59.8%. Diluted net income per share and non-GAAP diluted net income per share: Diluted net income per share was $0.18, versus $0.31, while non-GAAP diluted net income per share was $0.36, versus $0.45. Operating cash flow and free cash flow: Operating cash flow of $93.3 million, versus $93.9 million, a decrease of 1% year-over-year, and free cash flow of $91.3 million, versus $91.6 million, a decrease of less than 1% year-over-year. Financial Outlook Doximity is providing guidance for its fiscal third quarter ending December 31, 2026 as follows: Revenue between $195 million and $196 million. Adjusted EBITDA between $102.5 million and $103.5 million. Doximity is updating guidance for its fiscal year ending March 31, 2027 as follows: Revenue between $678 million and $683 million. Adjusted EBITDA between $317 million and $325 million. For more detailed financial commentary, please refer to the “Modeling Considerations” appendix in our prepared remarks. Conference Call Information Doximity posted prepared remarks on its investor relations website at https://investors.doximity.com. Doximity will host a webcast today at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to discuss these financial results. To listen to a live audio webcast, please visit the Company’s Investor Relations page at https://investors.doximity.com. The recorded webcast will be available on the Company’s Investor Relations page shortly after the call. About Doximity Founded in 2010, Doximity is the leading digital platform for U.S. medical professionals. The company's network members include more than 85% of U.S. physicians. With AI-powered clinical reference and search capabilities, Doximity helps doctors access trusted, peer-reviewed information and medical literature. Doximity's mission is to help doctors be more productive so they can provide better care for their patients. Forward-Looking Statements This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act. Forward-looking statements are all statements other than statements of historical fact, and specifically include statements regarding guidance and future business and financial results. These statements reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations, or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors including, without limitation, those set forth in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended March 31, 2026 and as may be updated in any subsequent Quarterly Reports on Form 10-Q. Moreover, we operate in a very competitive and rapidly changing environment. New risks and uncertainties emerge from time to time, and it is not possible for us to predict all risks and uncertainties that could cause actual results to differ materially from those contained in our forward-looking statements. The forward-looking statements made in this press release relate only to management’s beliefs and assumptions as of this date. We assume no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law. DOXIMITY, INC. CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) (unaudited) September 30, 2026 March 31, 2026 Assets Current assets: Cash and cash equivalents $ 218,614 $ 219,178 Marketable securities 494,615 529,423 Accounts receivable, net 166,113 144,783 Prepaid expenses and other current assets 42,200 50,880 Total current assets 921,542 944,264 Property and equipment, net 19,827 18,080 Deferred income tax assets 26,070 31,984 Operating lease right-of-use assets 6,362 7,140 Intangible assets, net 31,444 35,325 Goodwill 84,973 84,973 Other assets 1,552 1,921 Total assets $ 1,091,770 $ 1,123,687 Liabilities and Stockholders’ Equity Current liabilities: Accounts payable $ 6,304 $ 4,009 Accrued expenses and other current liabilities 35,865 42,804 Deferred revenue, current 100,227 106,050 Operating lease liabilities, current 2,198 2,110 Total current liabilities 144,594 154,973 Deferred revenue, non-current 37 400 Operating lease liabilities, non-current 6,948 8,075 Other liabilities, non-current 11,707 9,402 Total liabilities 163,286 172,850 Stockholders' Equity Preferred stock — — Common stock 178 183 Additional paid-in capital 1,068,702 1,001,688 Accumulated other comprehensive income (loss) (1,653 ) 28 Accumulated deficit (138,743 ) (51,062 ) Total stockholders’ equity 928,484 950,837 Total liabilities and stockholders’ equity $ 1,091,770 $ 1,123,687 DOXIMITY, INC. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) (unaudited) Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 Revenue $ 174,537 $ 168,525 $ 331,155 $ 314,438 Cost of revenue (1) 25,346 16,425 49,038 32,218 Gross profit 149,191 152,100 282,117 282,220 Operating expenses (1) : Research and development 41,961 30,202 80,439 57,001 Sales and marketing 46,892 39,168 91,941 75,533 General and administrative 16,416 19,049 32,172 31,488 Total operating expenses 105,269 88,419 204,552 164,022 Income from operations 43,922 63,681 77,565 118,198 Other income, net 6,405 9,258 13,124 18,888 Income before income taxes 50,327 72,939 90,689 137,086 Provision for income taxes 15,597 10,880 31,645 21,707 Net income $ 34,730 $ 62,059 $ 59,044 $ 115,379 Net income per share attributable to Class A and Class B common stockholders: Basic $ 0.19 $ 0.33 $ 0.33 $ 0.61 Diluted $ 0.18 $ 0.31 $ 0.31 $ 0.57 Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders: Basic 178,674 187,705 180,611 187,844 Diluted 187,804 200,745 189,475 200,952 (1) Costs and expenses include stock-based compensation expense as follows (in thousands): Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 Cost of revenue $ 3,036 $ 2,844 $ 6,228 $ 5,824 Research and development 16,028 9,862 31,587 16,511 Sales and marketing 12,696 10,508 25,121 18,218 General and administrative 8,805 6,260 14,381 10,786 Total stock-based compensation expense $ 40,565 $ 29,474 $ 77,317 $ 51,339 DOXIMITY, INC. CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited) Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 Cash flows from operating activities Net income $ 34,730 $ 62,059 $ 59,044 $ 115,379 Adjustments to reconcile net income to net cash provided by operating activities: Depreciation and amortization 4,353 3,469 8,640 6,263 Stock-based compensation, net of amounts capitalized 40,565 29,474 77,317 51,339 Non-cash lease expense 391 454 778 904 Accretion of discount on marketable securities, net (358 ) (2,199 ) (925 ) (4,687 ) Amortization of deferred contract costs 3,858 2,876 8,158 6,772 Other 358 294 20 (114 ) Changes in operating assets and liabilities: Accounts receivable 11,366 12,396 (21,968 ) (985 ) Prepaid expenses and other assets 5,259 7,685 14,384 3,451 Deferred contract costs (2,577 ) (2,584 ) (5,219 ) (4,549 ) Accounts payable, accrued expenses and other liabilities 4,701 (2,168 ) 2,268 (2,333 ) Deferred revenue (8,834 ) (17,241 ) (6,186 ) (14,268 ) Operating lease liabilities (527 ) (571 ) (1,039 ) (1,127 ) Net cash provided by operating activities 93,285 93,944 135,272 156,045 Cash flows from investing activities Cash paid for acquisition, net of cash acquired — (26,528 ) — (26,528 ) Purchases of property and equipment — — (62 ) — Internal-use software development costs (1,953 ) (2,369 ) (4,275 ) (4,335 ) Purchases of marketable securities (168,476 ) (128,266 ) (183,222 ) (268,200 ) Maturities of marketable securities 86,396 125,452 212,467 270,031 Sales of marketable securities — — 4,049 — Net cash provided by (used in) investing activities (84,033 ) (31,711 ) 28,957 (29,032 ) Cash flows from financing activities Proceeds from issuance of common stock upon exercise of stock options and common stock warrants 908 2,398 3,988 4,796 Proceeds from issuance of common stock in connection with the employee stock purchase plan 1,288 1,816 1,288 1,816 Taxes paid related to net share settlement of equity awards (9,948 ) (12,566 ) (16,922 ) (24,493 ) Repurchase of common stock (54,198 ) (21,893 ) (145,831 ) (144,248 ) Payment of contingent consideration related to a business combination — — (5,024 ) (5,249 ) Payment of excise taxes on share repurchases (2,292 ) — (2,292 ) — Net cash used in financing activities (64,242 ) (30,245 ) (164,793 ) (167,378 ) Net increase (decrease) in cash and cash equivalents (54,990 ) 31,988 (564 ) (40,365 ) Cash and cash equivalents, beginning of period 273,604 137,261 219,178 209,614 Cash and cash equivalents, end of period $ 218,614 $ 169,249 $ 218,614 $ 169,249 Supplemental disclosures of cash flow information Cash paid for taxes, net of refunds $ 10,126 $ 14,369 $ 14,116 $ 19,347 Non-GAAP Financial Measures To supplement our condensed consolidated financial statements, which are prepared and presented in accordance with accounting principles generally accepted in the United States (“GAAP”), the Company uses the following non-GAAP measures of financial performance: Non-GAAP gross profit, non-GAAP gross margin, non-GAAP operating income, non-GAAP net income, non-GAAP net income margin, and non-GAAP basic and diluted net income per common share: We exclude the effect of acquisition and other related expenses, stock-based compensation expense, amortization of acquired intangible assets, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, and change in fair value of contingent earn-out consideration liability from non-GAAP gross profit, non-GAAP gross margin and non-GAAP operating income. Non-GAAP net income and non-GAAP net income margin are further adjusted for estimated income tax on such adjustments. We calculate income taxes on the adjustments by applying an estimated annual effective tax rate to the adjustments. Non-GAAP basic and diluted net income per common share is non-GAAP net income attributable to common stockholders divided by the weighted average number of shares. For both basic and diluted non-GAAP net income per share, the weighted average shares we use in computing non-GAAP net income per share is equal to our GAAP weighted average shares. Non-GAAP gross margin represents non-GAAP gross profit as a percentage of revenue and non-GAAP net income margin represents non-GAAP net income as a percentage of revenue. Adjusted EBITDA and adjusted EBITDA margin: We define adjusted EBITDA as net income before interest, income taxes, depreciation, and amortization, and as further adjusted for acquisition and other related expenses, stock-based compensation expense, legal fees associated with certain non-ordinary course legal matters including the shareholder class action litigation, change in fair value of contingent earn-out consideration liability, and other income, net. Net income margin represents net income as a percentage of revenue and adjusted EBITDA margin represents adjusted EBITDA as a percentage of revenue. Free cash flow: We calculate free cash flow as cash flow from operating activities less purchases of property and equipment, purchases of intangible assets, and internal-use software development costs. We use these non-GAAP financial measures internally for financial and operational decision-making purposes and as a means to evaluate period-to-period comparisons. Non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP financial measures and should be read only in conjunction with our condensed consolidated financial statements prepared in accordance with GAAP. Our presentation of non-GAAP financial measures may not be comparable to similar measures used by other companies. We encourage investors to carefully consider our results under GAAP, as well as our supplemental non-GAAP information and the reconciliation between these presentations, to more fully understand our business. Please see the tables included at the end of this release for the reconciliation of GAAP to non-GAAP results. Key Business Metrics Net revenue retention rate: Our net revenue retention rate compares our subscription revenue from the same set of customers across comparable periods, and reflects customer renewals, expansion, contraction, and churn. Net revenue retention rate is calculated by taking the trailing 12-month (“TTM”) subscription-based revenue from our customers that had revenue in the prior TTM period and dividing that by the total subscription-based revenue for the prior TTM period. For the purposes of this calculation, subscription revenue excludes subscriptions for individuals and small practices and other non-recurring items. Our net revenue retention rate is directly tied to our revenue growth rate and thus fluctuates as that growth rate fluctuates. Customers with trailing 12-month subscription revenue greater than $500,000: The number of customers with TTM subscription revenue greater than $500,000 is a key indicator of the scale of our business and the value we create for large customers, and is calculated by counting the number of customers that contributed more than $500,000 in subscription revenue in the TTM period. Our customer count is subject to adjustments for acquisitions, consolidations, spin-offs, and other market activity, and we present our total customer count for historical periods reflecting these adjustments. Quarterly unique active providers using our workflow tools: Quarterly unique active providers 1 using our Workflow Tools is a measure of our platform’s usage and adoption among healthcare providers on our platform. We calculate the number of unique active providers by counting providers who securely log in and use any of the following workflow functions on our technology platform during the quarter: placing phone calls or video calls lasting more than 10 seconds, sending voicemails, or sending secure text messages using our Dialer communications tools; sending or receiving faxes; submitting a prompt on Ask (formerly DoxGPT), our HIPAA‑compliant generative AI clinical research tool and writing assistant; conducting research on prescription drugs; reviewing AI responses for our PeerCheck feature; scheduling via our on-call scheduling tool, Amion; or using our HIPAA-compliant ambient note taking tool, Scribe, for a patient visit. Each provider is counted once per quarter, even if they use multiple tools or use them many times. __________________________ 1 Providers are health care professionals with clinical / prescribing roles, specifically Physicians (MD/DO), Nurse practitioners (NPs), Certified registered nurse anesthetists (CRNAs), Physician assistants (PAs), Pharmacists, and Medical students. Reconciliation of GAAP to Non-GAAP Financial Measures The following tables reconcile the specific items excluded from GAAP metrics in the calculation of non-GAAP metrics for the periods shown below: Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 (unaudited) (in thousands, except percentages) Net income $ 34,730 $ 62,059 $ 59,044 $ 115,379 Adjusted to exclude the following: Acquisition and other related expenses — 1,188 — 1,616 Stock-based compensation 40,565 29,474 77,317 51,339 Depreciation and amortization 4,353 3,469 8,640 6,263 Provision for income taxes 15,597 10,880 31,645 21,707 Change in fair value of contingent earn-out consideration liability — 91 90 259 Legal expenses 25 2,927 25 2,927 Other income, net (6,405 ) (9,258 ) (13,124 ) (18,888 ) Adjusted EBITDA $ 88,865 $ 100,830 $ 163,637 $ 180,602 Revenue $ 174,537 $ 168,525 $ 331,155 $ 314,438 Net income margin 20 % 37 % 18 % 37 % Adjusted EBITDA margin 51 % 60 % 49 % 57 % Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 (unaudited) (in thousands) Net cash provided by operating activities $ 93,285 $ 93,944 $ 135,272 $ 156,045 Purchases of property and equipment — — (62 ) — Internal-use software development costs (1,953 ) (2,369 ) (4,275 ) (4,335 ) Free cash flow $ 91,332 $ 91,575 $ 130,935 $ 151,710 Other cash flow components: Net cash provided by (used in) investing activities $ (84,033 ) $ (31,711 ) $ 28,957 $ (29,032 ) Net cash used in financing activities $ (64,242 ) $ (30,245 ) $ (164,793 ) $ (167,378 ) Three Months Ended September 30, Six Months Ended September 30, 2026 2025 2026 2025 (unaudited) (in thousands, except per share data and percentages) GAAP cost of revenue $ 25,346 $ 16,425 $ 49,038 $ 32,218 Adjusted to exclude the following: Stock-based compensation (3,036 ) (2,844 ) (6,228 ) (5,824 ) Amortization of acquired intangibles (935 ) — (1,870 ) — Non-GAAP cost of revenue $ 21,375 $ 13,581 $ 40,940 $ 26,394 GAAP gross profit $ 149,191 $ 152,100 $ 282,117 $ 282,220 Adjusted to exclude the following: Stock-based compensation 3,036 2,844 6,228 5,824 Amortization of acquired intangibles 935 — 1,870 — Non-GAAP gross profit $ 153,162 $ 154,944 $ 290,215 $ 288,044 GAAP gross margin 85.5 % 90.3 % 85.2 % 89.8 % Non-GAAP gross margin 87.8 % 91.9 % 87.6 % 91.6 % GAAP research and development expense $ 41,961 $ 30,202 $ 80,439 $ 57,001 Adjusted to exclude the following: Stock-based compensation (16,028 ) (9,862 ) (31,587 ) (16,511 ) Amortization of acquired intangibles — (623 ) — (623 ) Non-GAAP research and development expense $ 25,933 $ 19,717 $ 48,852 $ 39,867 GAAP sales and marketing expense $ 46,892 $ 39,168 $ 91,941 $ 75,533 Adjusted to exclude the following: Stock-based compensation (12,696 ) (10,508 ) (25,121 ) (18,218 ) Amortization of acquired intangibles (1,005 ) (1,002 ) (2,011 ) (2,004 ) Change in fair value of contingent earn-out consideration liability — (91 ) (90 ) (259 ) Non-GAAP sales and marketing expense $ 33,191 $ 27,567 $ 64,719 $ 55,052 GAAP general and administrative expense $ 16,416 $ 19,049 $ 32,172 $ 31,488 Adjusted to exclude the following: Acquisition and other related expenses — (1,188 ) — (1,616 ) Stock-based compensation (8,805 ) (6,260 ) (14,381 ) (10,786 ) Legal expenses (25 ) (2,927 ) (25 ) (2,927 ) Non-GAAP general and administrative expense $ 7,586 $ 8,674 $ 17,766 $ 16,159 GAAP operating expense $ 105,269 $ 88,419 $ 204,552 $ 164,022 Adjusted to exclude the following: Acquisition and other related expenses — (1,188 ) — (1,616 ) Stock-based compensation (37,529 ) (26,630 ) (71,089 ) (45,515 ) Amortization of acquired intangibles (1,005 ) (1,625 ) (2,011 ) (2,627 ) Change in fair value of contingent earn-out consideration liability — (91 ) (90 ) (259 ) Legal expenses (25 ) (2,927 ) (25 ) (2,927 ) Non-GAAP operating expense $ 66,710 $ 55,958 $ 131,337 $ 111,078 GAAP operating income $ 43,922 $ 63,681 $ 77,565 $ 118,198 Adjusted to exclude the following: Acquisition and other related expenses — 1,188 — 1,616 Stock-based compensation 40,565 29,474 77,317 51,339 Amortization of acquired intangibles 1,940 1,625 3,881 2,627 Change in fair value of contingent earn-out consideration liability — 91 90 259 Legal expenses 25 2,927 25 2,927 Non-GAAP operating income $ 86,452 $ 98,986 $ 158,878 $ 176,966 GAAP net income $ 34,730 $ 62,059 $ 59,044 $ 115,379 Adjusted to exclude the following: Acquisition and other related expenses — 1,188 — 1,616 Stock-based compensation 40,565 29,474 77,317 51,339 Amortization of acquired intangibles 1,940 1,625 3,881 2,627 Change in fair value of contingent earn-out consideration liability — 91 90 259 Legal expenses 25 2,927 25 2,927 Income tax effect of non-GAAP adjustments (1) (8,931 ) (7,414 ) (17,076 ) (12,341 ) Non-GAAP net income $ 68,329 $ 89,950 $ 123,281 $ 161,806 Non-GAAP net income margin 39.1 % 53.4 % 37.2 % 51.5 % Weighted-average shares used in computing net income per share attributable to Class A and Class B common stockholders: Basic 178,674 187,705 180,611 187,844 Diluted 187,804 200,745 189,475 200,952 Non-GAAP net income per share attributable to Class A and Class B stockholders: Basic $ 0.38 $ 0.48 $ 0.68 $ 0.86 Diluted $ 0.36 $ 0.45 $ 0.65 $ 0.81 (1) For the three and six months ended September 30, 2026 and 2025, management used an estimated annual effective non-GAAP tax rate of 21.0%. Investor Relations Contact: Perry Gold ir@doximity.com Media Contact: Richard George pr@doximity.com Source: Doximity
View original release